Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipilimumab with or without gp100 vaccine versus gp100 vaccine alone in previously treated unresectable stage III/IV melanoma
2004-005059-32Phase 3Completed
- Sponsor
- Medarex, Inc.
- Start
- Feb 2005
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in melanoma comparing Ipilimumab monotherapy, Ipilimumab plus gp100 melanoma peptide vaccine and gp100 melanoma peptide vaccine monotherapy (3 arms). Primary endpoint: Overall survival. Started Feb 2005; status: completed.
02
Drugs
ipilimumabgp100:209-217(210M)
03
Conditions
melanoma
Beyond the preview
Go deeper on 2004-005059-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-005059-32.